Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT in treatment-resistant axial spondyloarthritis
2023-504852-89-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in axial spondyloarthritis (axSpA) comparing MaaT033 with Placebo (2 arms). Primary endpoints: Change in MSP richness from baseline to Day 42 and ASAS20 response at Day 42. Planned start Apr 2024; status: authorised.
02
Drugs
MaaT-033
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on 2023-504852-89-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504852-89-00.